Once-Weekly Insulin Promising in Phase 3 Trial in Type 2 Diabetes Once-Weekly Insulin Promising in Phase 3 Trial in Type 2 Diabetes
Novo Nordisk ' s insulin icodec was superior in lowering A1c compared with daily degludec without increasing the risk for moderate or severe hypoglycemia in adults with type 2 diabetes already taking basal insulin.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 29, 2022 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news

Bespoke Apothecary LLC - 641573 - 09/28/2022
Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 29, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Olokizumab Shows Efficacy After Nonresponse to TNF Inhibitors Olokizumab Shows Efficacy After Nonresponse to TNF Inhibitors
The most likely use of olokizumab in clinical practice, if it is approved, is for patients with inadequate responses to TNF inhibitors.MDedge News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 29, 2022 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Proper Trade LLC/My Stellar Lifestyle Issues Voluntary Nationwide Recall of Wonder Pill Capsules Due to the Presence of Undeclared Tadalafil
Proper Trade LLC/My Stellar Lifestyle is voluntarily recalling Wonder Pill lot 20210912 and lot 31853-501 (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 28, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Remdesivir and Acute Kidney or Liver Injury Risk in COVID-19 Remdesivir and Acute Kidney or Liver Injury Risk in COVID-19
Remdesivir has emerged as a treatment option for hospitalized COVID-19 patients, but what do we currently know about the potential risks for acute kidney or liver injury?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option The approval is based on totality of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 27, 2022 Category: Drugs & Pharmacology Source Type: news

FDA Approves Iheezo (chloroprocaine hydrochloride ophthalmic gel) for Ocular Surface Anesthesia
Iheezo Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 Years Iheezo was Licensed by Harrow for the U.S.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 27, 2022 Category: Drugs & Pharmacology Source Type: news

Eugia US LLC Issues Voluntary Nationwide Recall of Acyclovir Sodium Injection 500 mg per 10 mL (50 mg/mL), Due to the Presence of Particulate Matter
East Windsor, New Jersey, Eugia US LLC (formerly AuroMedics Pharma LLC) has initiated a voluntary recall of lot number AC22006 of AuroMedics Acyclovir Sodium Injection 500 mg per 10 mL (50 mg/mL), 10 mL single dose vial to the consumer level from the U.S. market due to a product complaint for the pr (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 27, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Zhejiang Tianyu Pharmaceutical Co., Ltd. - 631054 - 08/17/2022
CGMP/Active Pharmaceutical Ingredient (API)/Adulterated (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 27, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Muscle Sports Products, LLC - 625731 - 09/23/2022
Unapproved New Drugs/Misbranded (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 27, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

System Kosmetik Produktionsgesellschaft fur kosmetische Gmbh - 632727 - 09/09/2022
CGMP/Finished Pharmaceuticals/Adulterated (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 27, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Providing Over-the-Counter Monograph Submissions in Electronic Format
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 27, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Schools and community groups invited to get creative for brain art competition
Schools and community groups across Bristol and the surrounding area are invited to take part in the University of Bristol's brain art competition and have their work displayed in public. (Source: University of Bristol news)
Source: University of Bristol news - September 27, 2022 Category: Universities & Medical Training Tags: Public engagement; Faculty of Life Sciences, Faculty of Life Sciences, School of Physiology, Pharmacology and Neuroscience, Institutes, Institutes, Elizabeth Blackwell; Press Release Source Type: news

FDA Approves Omlonti (omidenepag isopropyl ophthalmic solution) for Reduction of Elevated Intraocular Pressure in Primary Open-Angle Glaucoma or Ocular Hypertension
EMERYVILLE, Calif.& UBE, Japan--(BUSINESS WIRE) September 26, 2022 --Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 26, 2022 Category: Drugs & Pharmacology Source Type: news

Walfer Corporation dba Wallace Pharmacy - 611017 - 09/20/2022
Compounding Pharmacy/Adulterated Drug Products (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 26, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news